Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers

About Oblique Therapeutics About Oblique Therapeutics Oblique Therapeutics is a biotechnology company that focuses on developing new therapeutic methods for treating severe illnesses, especially in the area of pain management and also for other conditions. The company uses pioneering technology and innovative research methods to discover and develop new drug candidates. About the KTH Royal Institute of Technology (KTH) KTH is the biggest technical university inSwedenand is one...

About Oblique Therapeutics

Oblique Therapeutics is a biotechnology company that focuses on developing new therapeutic methods for treating severe illnesses, especially in the area of pain management and also for other conditions. The company uses pioneering technology and innovative research methods to discover and develop new drug candidates.

About the KTH Royal Institute of Technology (KTH)

KTH is the biggest technical university in Sweden and is one of Europe's leading technical institutions. The university is known for its research and education in technology and science, and its advanced research infrastructure, including the supercomputer, supports a broad range of scientific disciplines. The supercomputer in question is one of the most green computers in the world thanks to its energy-efficient architecture and due to using renewable electricity and recycling heat.

"We are delighted to collaborate with KTH and benefit from their advanced computational resources and to combine those with our innovative approach in order to accelerate our research and development achievements," says the leading researcher in the project, Dr. Anna Reymer, from Oblique Therapeutics. "This collaboration will further strengthen our position within the biotechnology branch and increase our chances of delivering ground-breaking therapies to patients all over the world."

"On behalf of KTH, PDC is proud to contribute to the Swedish high-tech industry. The collaboration with Oblique Therapeutics is an outstanding example of this and falls within the scope of biotechnology, which is an area where KTH researchers are highly active and very successful," says Patrick Norman, PDC's director.

For additional information, pls contact: Anna Reymer ([email protected]), Olof Larsson ([email protected]) & Michaela Barth ([email protected]).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oblique-therapeutics-ab/r/oblique-therapeutics-and-the-kth-royal-institute-of-technology--kth--have-entered-into-a-strategic-c,c4003211

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/oblique-therapeutics-and-the-kth-royal-institute-of-technology-kth-have-entered-into-a-strategic-collaboration-to-analyse-protein-structures-using-supercomputers-302175679.html